These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2388648)

  • 1. Induction of dyskinesias.
    Mov Disord; 1990; 5(3):265-6. PubMed ID: 2388648
    [No Abstract]   [Full Text] [Related]  

  • 2. Levodopa, manganese, and degenerations of the brain.
    Cotzias GC
    Harvey Lect; 1974; 68():115-47. PubMed ID: 4452625
    [No Abstract]   [Full Text] [Related]  

  • 3. Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response.
    Maggio R; Barbier P; Corsini GU
    J Neural Transm Suppl; 1995; 45():133-6. PubMed ID: 8748618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Problems arising during chronic treatment with L-dopa for Parkinson's disease: changes in response to treatment.
    Caraceni TA; Girotti F; Giovannini P; Parati E
    J Neural Transm Suppl; 1986; 22():189-99. PubMed ID: 3537210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The neuropharmacology of abnormal involuntary movement disorders (the dyskinesias).
    Marsden CD
    Mod Trends Neurol; 1975; 6():141-66. PubMed ID: 127927
    [No Abstract]   [Full Text] [Related]  

  • 6. Apomorphine test for dopaminergic responsiveness: a dose assessment study.
    Bonuccelli U; Piccini P; Del Dotto P; Rossi G; Corsini GU; Muratorio A
    Mov Disord; 1993 Apr; 8(2):158-64. PubMed ID: 8474482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous dopaminergic stimulation for Parkinson's disease: facts and fancy.
    Obeso JA; Grandas F; Vaamonde J; Luquin MR; Martinez-Lage JM
    Funct Neurol; 1988; 3(4):413-27. PubMed ID: 3072277
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
    Bravi D; Davis TL; Mouradian MM; Chase TN
    Mov Disord; 1993 Apr; 8(2):195-7. PubMed ID: 8097280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected findings with apomorphine and their possible consequences.
    Cotzias GC; Mena I; Papavasiliou PS; Mendez J
    Adv Neurol; 1974; 5():295-9. PubMed ID: 4440577
    [No Abstract]   [Full Text] [Related]  

  • 10. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors.
    Olanow CW; Obeso JA
    Neurology; 2000; 55(11 Suppl 4):S72-7; discussion S78-81. PubMed ID: 11147513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Stocchi F
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S9-S15. PubMed ID: 19131046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa: rational and irrational pharmacology.
    Nutt JG
    Ann Neurol; 1994 Jul; 36(1):4-5. PubMed ID: 8024259
    [No Abstract]   [Full Text] [Related]  

  • 14. Parkinson's disease. The L-dopa era.
    Yahr MD
    Adv Neurol; 1993; 60():11-7. PubMed ID: 8420128
    [No Abstract]   [Full Text] [Related]  

  • 15. Sustained-release levodopa in parkinsonian patients with nocturnal disabilities.
    Van den Kerchove M; Jacquy J; Gonce M; De Deyn PP
    Acta Neurol Belg; 1993; 93(1):32-9. PubMed ID: 8451915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease.
    Wenning GK; Bösch S; Luginger E; Wagner M; Poewe W
    Adv Neurol; 1999; 80():545-8. PubMed ID: 10410769
    [No Abstract]   [Full Text] [Related]  

  • 17. Parkinson's disease: new treatments.
    Stewart RM
    Compr Ther; 1981 Apr; 7(4):38-44. PubMed ID: 7237986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenge tests to predict the dopaminergic response in untreated Parkinson's disease.
    Hughes AJ; Lees AJ; Stern GM
    Neurology; 1991 Nov; 41(11):1723-5. PubMed ID: 1944899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tics in a patient with Parkinson's disease.
    Shale H; Fahn S; Mayeux R
    Mov Disord; 1986; 1(1):79-83. PubMed ID: 3504234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three types of akinesia in the progressive course of Parkinson's disease.
    Narabayashi H
    Adv Neurol; 1993; 60():18-24. PubMed ID: 8093577
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.